Hedgehog Drug Development Services

Alfa Cytology is an expert provider of Hedgehog Drug Development Services, offering tailor-made solutions for the design, development, and characterization of Hedgehog (Hh) signaling pathway inhibitors. Leveraging our unparalleled expertise in drug discovery and development, we assure you that our comprehensive suite of services will fully support your research and development efforts in this area.

Introduction to Hedgehog Pathway

Hh is a signaling pathway that plays a key role in embryonic development and tissue homeostasis. Named after the Drosophila protein Hedgehog, it was first discovered regulating embryonic segmentation in fruit flies. Aberrant activation or dysregulation of the Hh pathway has been implicated in the development and progression of various cancers, including leukemia. This means that hyperactivity causes uncontrolled cell growth and survival in this special case that might lead to resistance to therapy.

Fig. 1. Simplified overview of the Hh signaling pathway in the (A) inactive state and (B) active state. (Jamieson, C. et al., 2020)

We design inhibitors targeting Smoothened (SMO) and glioma-associated oncogene homolog (GLI), based on their structure, and develop key targets for new drugs to treat malignant tumors, including acute myeloid leukemia.

SMO Inhibitors

• Design and Synthesis
  We will design and synthesize alkaloid cyclopamine based on its structure. Moreover, efforts will be made to optimize the structure of the cyclopamine derivatives for increased specificity, potency, and solubility, thereby making them candidates for clinical trials.
• Drug Screen
  Using our development systems and available screening methods, we are capable of screening a large number of compound libraries against alkaloid cyclopamine in search of novel SMO antagonists. We would then be able to establish further capabilities and conduct functional optimization of these antagonists toward their extended use.
• Combination Therapy
  Compared to monotherapy, the combination of glasdegib with chemotherapy demonstrates better clinical activity in treating acute myeloid leukemia. We possess significant experience with the development of methodologies to combine glasdegib with chemotherapy, enabling you to investigate optimal chemotherapy drug combinations.
• Addressing Drug Resistance
  Our service in glasdegib and chemotherapy combination development will offer great insight into resisting such SMO inhibitors in specific tumor types.

GLI Inhibitors

Evaluation of Hedgehog Pathway Inhibitors

Comprehensive analyses can be done to study the efficacy of Hedgehog Pathway inhibitors and further examine substantial potential at later development stages.

Advantages of Our Services

• Research and experience in developing numerous inhibitors.
• A plethora of databases of therapeutics.
• Good work, quality service, and subject matter.
• Good quality experimental results.
• Development of multiple therapy for Hedgehog pathway inhibitors.

With the belief that their very meaning and goal are directed providently, Alfa Cytology is committed to targeted high-quality drug development services in the pursuit of compounds inhibiting the Hedgehog pathway, thus giving new directions for acute myeloid leukemia therapies and other types of neoplasms derived from hematopoietic origin. Contact us now to discuss your requirements and how our services could help in your endeavor of developing Hedgehog pathway-targeted inhibitors.